Use of PZQ will increase in the foreseeable future, whether given alone or coadministered
with other anthelminthics in integrated control programmes. PZQ resistance remains a threat …

The current approach of morbidity control of schistosomiasis, a helminth disease of poverty
with considerable public health and socioeconomic impact, is based on preventive …

Helminth infections are responsible for a considerable public health burden, yet the current
drug armamentarium is small. Given the high cost of drug discovery and development, the …

Schistosomiasis is a disease caused by parasitic trematode worms (schistosomes) that
currently affects 200 million people living in tropical and subtropical environments. It is a …

The last half-century of schistosomiasis control activities in China have brought down the
overall prevalence of human infection with Schistosoma japonicum to less than 10% of the …

Background Extensive use of praziquantel for treatment and control of schistosomiasis
requires a comprehensive understanding of efficacy and safety of various doses for different …

The morbidity caused by schistosomiasis has been controlled in China, Egypt and the
Philippines mainly by the widespread use of the safe and efficacious drug praziquantel …

The morbidity due to schistosomiasis has been shown to be greater than was previously
thought. The reduction in morbidity of schistosomiasis by control programmes has been …

Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis
control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of …

Background Praziquantel has been used as first-line drug for chemotherapy of
schistosomiasis since 1984. Besides praziquantel, artemether and artesunate have also …